Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aralez Pharmaceuticals Inc.

http://aralez.com/

Latest From Aralez Pharmaceuticals Inc.

Crinetics May Have Drug Profile To Take Leading Position In Acromegaly

Reporting a second positive Phase III trial for oral paltusotine, Crinetics plans an NDA later this year to position its drug against competing injectable somatostatin analogs.

Clinical Trials Drug Approval Standards

Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements

Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.

Financing Business Strategies

Unpartnered Assets To Watch In 2024

Licensing serves as a strategic R&D avenue for major developers amid a shrinking M&A market. In Vivo has detected five high-value unpartnered assets that might be the focus of dealmaking activity in the coming months. 

Growth Commercial

Glaukos Gets Approval For Glaucoma Implant, With A Catch

Glaukos got US FDA approval for its intracameral implant of travoprost for glaucoma and hopes the product will work for up to three years. It also set a high goal for first-year sales.

Approvals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Medical Futures Inc.
    • POZEN Inc.
    • Stellar Pharmaceuticals, Inc. (SLXCF)
    • Tribute Pharmaceuticals Inc.
UsernamePublicRestriction

Register